The aim of the present study was to evaluate the effect of joint immobilization on morphometric parameters and glycogen content of soleus muscle treated with clenbuterol. Male Wistar (3-4 months old) rats were divided into 4 groups (N = 6 for each group): control, clenbuterol, immobilized, and immobilized treated with clenbuterol. Immobilization was performed with acrylic resin orthoses and 10 μg/kg body weight clenbuterol was administered subcutaneously for 7 days. The following parameters were measured the next day on soleus muscle: weight, glycogen content, cross-sectional area, and connective tissue content. The clenbuterol group showed an increase in glycogen (81.6%, 0.38 ± 0.09 vs 0.69 ± 0.06 mg/100 g; P < 0.05) without alteration in weight, cross-sectional area or connective tissue compared with the control group. The immobilized group showed a reduction in muscle weight (34.2%, 123.5 ± 5.3 vs 81.3 ± 4.6 mg; P < 0.05), glycogen content (31.6%, 0.38 ± 0.09 vs 0.26 ± 0.05 mg/100 mg; P < 0.05) and cross-sectional area (44.1%, 2574.9 ± 560.2 vs 1438.1 ± 352.2 μm2; P < 0.05) and an increase in connective tissue (216.5%, 8.82 ± 3.55 vs 27.92 ± 5.36%; P < 0.05). However, the immobilized + clenbuterol group showed an increase in weight (15.9%; 81.3 ± 4.6 vs 94.2 ± 4.3 mg; P < 0.05), glycogen content (92.3%, 0.26 ± 0.05 vs 0.50 ± 0.17 mg/100 mg; P < 0.05), and cross-sectional area (19.9%, 1438.1 ± 352.2 vs 1724.8 ± 365.5 μm2; P < 0.05) and a reduction in connective tissue (52.2%, 27.92 ± 5.36 vs 13.34 ± 6.86%; P < 0.05). Statistical analysis was performed using Kolmogorov-Smirnov and homoscedasticity tests. For the muscle weight and muscle glycogen content, two-way ANOVA and the Tukey test were used. For the cross-sectional area and connective tissue content, Kruskal-Wallis and Tukey tests were used. This study emphasizes the importance of anabolic pharmacological protection during immobilization to minimize skeletal muscle alterations resulting from disuse.
展开▼
机译：本研究的目的是评估关节固定对克仑特罗治疗的比目鱼肌形态参数和糖原含量的影响。将雄性Wistar（3-4个月大）大鼠分为4组（每组N ＝ 6）：对照，克仑特罗，固定的和用克仑特罗固定的治疗。用丙烯酸树脂矫形器进行固定，并皮下给予10μg/ kg体重的克仑特罗皮下注射7天。第二天在比目鱼肌上测量以下参数：体重，糖原含量，横截面积和结缔组织含量。与对照组相比，克仑特罗组糖原增加（81.6％，0.38±0.09 vs 0.69±0.06 mg / 100 g; P <0.05），而体重，横截面积或结缔组织没有改变。固定组显示肌肉重量减少（34.2％，123.5±5.3 vs 81.3±4.6 mg; P <0.05），糖原含量减少（31.6％，0.38±0.09 vs 0.26±0.05 mg / 100 mg; P <0.05）和横截面积（44.1％，2574.9±560.2 vs 1438.1±352.2μm2; P <0.05）和结缔组织增加（216.5％，8.82±3.55 vs 27.92±5.36％; P <0.05）。然而，固定化+克仑特罗组显示体重增加（15.9％; 81.3±4.6 vs 94.2±4.3 mg; P <0.05），糖原含量（92.3％，0.26±0.05 vs 0.50±0.17 mg / 100 mg; P < 0.05）和横截面积（19.9％，1438.1±352.2 vs 1724.8±365.5μm2; P <0.05）和结缔组织减少（52.2％，27.92±5.36 vs 13.34±6.86％; P <0.05）。使用Kolmogorov-Smirnov和均势检验进行统计分析。对于肌肉重量和肌肉糖原含量，使用双向ANOVA和Tukey检验。对于横截面积和结缔组织含量，使用Kruskal-Wallis和Tukey测试。这项研究强调了固定化过程中合成代谢药理保护的重要性，以最大程度地减少因停用而引起的骨骼肌改变。
展开▼
